This Peninsula biotech foresaw deals worth $3 billion. Now it's lining up a $57 million merger

This Peninsula biotech foresaw deals worth $3 billion. Now it's lining up a $57 million merger


The reverse merger between Redwood City-based OncoMed and Mereo BioPharma Group plc will give the London company a U.S. stock listing and seven experimental drugs. If the deal closes as expected in first-half 2019, it would close the books on OncoMed and validate the biotech industry's risk-stepping "biobucks" deals.



from Biotech News